Value through Innovation05 May 2015

Boehringer Ingelheim Press Releases

See the latest Boehringer Ingelheim news releases. To quickly find all news releases on a specific topic, please use the fulltext search.

Press Release Archive

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 next

Lilly and Boehringer Ingelheim Present Data at the 72nd American Diabetes Association Scientific Sessions® from Phase II Studies Comparing Investigational Novel Basal Insulin to Insulin Glargine

- EX UK. Medical Media Only.

New analysis presented at ADA shows improvement in albuminuria with linagliptin in patients at high risk of declining renal function

- EX US & UK. Medical Media Only.

New data demonstrate sustained glucose reduction and weight loss up to 90 weeks with investigational SGLT-2 inhibitor, empagliflozin*

- EX US & UK. Medical Media Only.

New linagliptin phase III data demonstrate significant reductions in blood glucose with no additional risk of hypoglycaemia when combined with insulin in patients with type 2 diabetes

- EX US & UK. Medical Media Only.

FDA affirms superiority of Pradaxa® (dabigatran etexilate) 150mg over warfarin in reduction of both ischaemic and haemorrhagic strokes

- For Non-US, Non-UK & Non-Canadian Media Only

Boehringer Ingelheim and Lilly to feature 30 presentations on type 1 and type 2 diabetes at the 72nd American Diabetes Association Scientific Sessions

- EX US & UK. Medical Media Only.

Afatinib* delivers unprecedented first line efficacy in patients with EGFR mutation positive lung cancer in registration trial

- For NON-US media only

Boehringer Ingelheim launches first-of-a-kind fundraising model to support disease awareness projects

- For NON-US Media Only

Boehringer Ingelheim expands development capacities with new technical centre


Boehringer Ingelheim further strengthens animal health presence in China: Manufacturing joint venture for veterinary vaccines


Jentadueto™ (linagliptin/metformin hydrochloride) tablets recommended for approval in the treatment of adults with Type 2 Diabetes in Europe

- For Non-U.S. and Non-UK Media

€100,000 in reward donations for projects fundraising to prevent atrial fibrillation-related strokes

- For NON-US Media Only

One million signatures needed to call upon World Health Organisation to save lives through education and improved management of atrial fibrillation

- For NON-US Media Only

Boehringer Ingelheim announces positive phase II results for once-daily tiotropium in asthma

- For Media outside the U.S., Canada and UK

Boehringer Ingelheim’s once-daily bronchodilator olodaterol* successfully completes Phase II clinical trial program in COPD

- For Media outside the U.S., Canada and UK

Switching to TWYNSTA® allows patients with uncontrolled hypertension on monotherapy to rapidly reach their blood pressure goals

- For Non-US and Non-UK Healthcare Media Only

Boehringer Ingelheim on growth path - Successful 2011 financial year


GLORIATM-AF Registry Program investigating use of antithrombotic therapy in 56,000 patients with atrial fibrillation at risk of stroke announced

- For non-US, UK & Canadian Media
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 next